This topic contains a solution. Click here to go to the answer

Author Question: Imani has little interest in sexual activity, which is beginning to cause problems in her ... (Read 53 times)

NClaborn

  • Hero Member
  • *****
  • Posts: 560
Imani has little interest in sexual activity, which is beginning to cause problems in her relationship. If she wants to increase her level of sexual desire, Imani is MOST likely to benefit from _________
 
  A) estrogen replacement therapy.
  B) Depo Provera.
  C) progesterone therapy.
  D) testosterone replacement therapy.

Question 2

Which of the following statements BEST describes the relationship between estrogens and female sexual motivation and behavior?
 
  A) Estrogens play an insignificant role in female sexual activity.
  B) Estrogen replacement therapy increases female sexual desire.
  C) Estrogen replacement therapy increases orgasmic capacity.
  D) At this time, research findings are contradictory.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

Gabe

  • Sr. Member
  • ****
  • Posts: 321
Answer to Question 1

D

Answer to Question 2

D




NClaborn

  • Member
  • Posts: 560
Reply 2 on: Jun 22, 2018
Excellent


robbielu01

  • Member
  • Posts: 336
Reply 3 on: Yesterday
:D TYSM

 

Did you know?

Most women experience menopause in their 50s. However, in 1994, an Italian woman gave birth to a baby boy when she was 61 years old.

Did you know?

In women, pharmacodynamic differences include increased sensitivity to (and increased effectiveness of) beta-blockers, opioids, selective serotonin reuptake inhibitors, and typical antipsychotics.

Did you know?

Women are 50% to 75% more likely than men to experience an adverse drug reaction.

Did you know?

Disorders that may affect pharmacodynamics include genetic mutations, malnutrition, thyrotoxicosis, myasthenia gravis, Parkinson's disease, and certain forms of insulin-resistant diabetes mellitus.

Did you know?

The U.S. Preventive Services Task Force recommends that all women age 65 years of age or older should be screened with bone densitometry.

For a complete list of videos, visit our video library